tiprankstipranks
Rapt Therapeutics price target raised to $6 from $4 at Wells Fargo
The Fly

Rapt Therapeutics price target raised to $6 from $4 at Wells Fargo

Wells Fargo raised the firm’s price target on Rapt Therapeutics (RAPT) to $6 from $4 and keeps an Overweight rating on the shares. With the in-license of a food allergy/CSU drug with a validated target and derisking Phase 1 pharmacokinetic-pharmacodynamic data supporting long dosing intervals, the firm sees significant upside for Rapt heading into proof-of-concept readouts starting in the second half of 2025.

Don't Miss Our Christmas Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App